[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4254
6. Fröhling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D, Harder L, Kreitmeier S, Scholl C, Caligiuri MA, Bloomfield CD, Döhner H, Döhner K: Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes Cancer; 2005 Apr;42(4):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.
  • To assess the prevalence of mutations in the CEBPA gene, which encodes the myeloid transcription factor CEBPA in specific cytogenetic subgroups, we initially studied 125 patients with acute myeloid leukemia (AML).
  • Five of the eight patients with del(9q) as the sole aberration or in combination with a single additional abnormality other than t(8;21) had CEBPA mutations associated with loss of CEBPA function.
  • We have shown for the first time that AML with del(9q) in the context of a noncomplex karyotype is strongly associated with CEBPA loss-of-function mutations.
  • Loss of a critical segment of 9q, most likely in 9q22, and disruption of CEBPA function possibly cooperate in the pathogenesis of del(9q) AML.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 9. Leukemia, Myeloid / genetics. Mutation. Transcription Factors / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Base Sequence. Cohort Studies. DNA Primers. Humans. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15645492.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 10114 0; United States / NCI NIH HHS / CA / CA 16058; United States / NCI NIH HHS / CA / CA 77658
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Transcription Factors
  •  go-up   go-down


7. Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM: Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol; 2005 May;32(4):313-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pyridopyrimidinones are a potent class of inhibitors of c-Abl kinase and Bcr-Abl kinase, the causative fusion protein in chronic myelogenous leukemia and Src family kinases.
  • The radioiodination of 4'-stannylpyridopyrimidinones was found to optimally occur via an iododestannylation with Na(124)I, Na(125)I or Na(131)I in the presence of an oxidant [30% H(2)O(2)/HOAc (1:3)/10 min] in 79-87% radiochemical yield with >99% radiochemical purity.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878500.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA064593; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P50 CA86438
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(4-iodophenylamino)pyrido(2,3-d)pyrimidin-7-one; 0 / Iodine Radioisotopes; 0 / PD 173074; 0 / Pyridones; 0 / Pyrimidines; 0 / Radiopharmaceuticals; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


8. Brennan P, Scélo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Seow A, Pompe-Kirn V, Martos C, Jonasson JG, Colin D, Boffetta P: Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer; 2005 Jul 11;93(1):159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma.
  • An analysis of other primary cancers in individuals with non-Hodgkin's lymphoma (NHL) can help to elucidate this cancer aetiology.
  • There was a 47% (95% confidence interval 43-51%) overall increase in the risk of a primary cancer after NHL.
  • A strongly significant (P<0.001) increase was observed for cancers of the lip, tongue, oropharynx*, stomach, small intestine, colon*, liver, nasal cavity*, lung, soft tissues*, skin melanoma*, nonmelanoma skin*, bladder*, kidney*, thyroid*, Hodgkin's lymphoma*, lymphoid leukaemia* and myeloid leukaemia.
  • Non-Hodgkin's lymphoma as a second primary was increased after cancers marked with an asterisk.
  • Patterns of risk indicate a treatment effect for lung, bladder, stomach, Hodgkin's lymphoma and myeloid leukaemia.
  • Bidirectional effects for several cancer sites of potential viral origin argue strongly for a role for immune suppression in NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):1-8 [15185336.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):431-7 [15006920.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:3-9 [4088304.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2002-9 [2004317.001]
  • [Cites] Cancer. 1992 May 1;69(9):2337-42 [1562981.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):387-94 [7812197.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):945-50 [8611412.001]
  • [Cites] Am J Epidemiol. 1997 Jun 15;145(12):1061-75 [9199536.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):25-8 [9456239.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1995;64:1-378 [16755705.001]
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):341-9 [10752985.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1344-7 [10755412.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2000;75 Pt 1:35-115 [10932818.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):288-93 [11410879.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):997-1005 [11592772.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):813-20 [11714109.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):223-9 [12509955.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2087-92 [14647142.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • (PMID = 15970927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101442; United States / NCI NIH HHS / CA / R03 CA101442-02
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361473
  •  go-up   go-down


9. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L: Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev; 2010 Mar;24(2):51-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with acute myeloid leukemia and those who have undergone allogeneic hematopoietic stem cell transplantation are at especially high risk.
  • [MeSH-major] Antifungal Agents / therapeutic use. Hematologic Diseases / complications. Immunocompromised Host. Mycoses / drug therapy

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20056300.001).
  • [ISSN] 1532-1681
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 128
  •  go-up   go-down


10. Naoghare PK, Kim MJ, Song JM: Uniform threshold intensity distribution-based quantitative multivariate imaging cytometry. Anal Chem; 2008 Jul 15;80(14):5407-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An acousto-optic tunable filter-based, quantitative multivariate imaging cytometer was set up to elucidate drug-induced cell death dynamics via cell viability and apoptosis/necrosis measurements in the human myeloid leukemia cell line, HL-60.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18512945.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J: Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer; 2006 Jan 15;106(2):346-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
  • BACKGROUND: Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models.
  • The median age of the patients was 62 years (range, 38-80 yrs) and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years (range, 0.3-13 yrs).
  • Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months.
  • [MeSH-major] Farnesyltranstransferase / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperidines / therapeutic use. Pyridines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342165.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Piperidines; 0 / Pyridines; 0 / Pyrimidines; 193275-84-2 / lonafarnib; 8A1O1M485B / Imatinib Mesylate; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


67. Joseph DE, Durosinmi MA: Neurological complications of chronic myeloid leukaemia: any cure? Niger J Clin Pract; 2008 Sep;11(3):246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological complications of chronic myeloid leukaemia: any cure?
  • OBJECTIVE: To attempt to explain the non-reversal, contrary to the widely held view, of the neurological deficits complicating chronic myeloid leukaemia.
  • METHOD: Using patients' case folders and haematological malignancy register all cases of chronic myeloid leukaemia seen in Jos University Teaching Hospital between July 1995 and June 2005 were retrospectively studied.
  • RESULTS: Thirty-three cases of chronic myeloid leukaemia were seen within the study period.
  • CONCLUSION: While the complications due to hyperleucocytosis-induced stasis recover following the conventional treatment, those due to other pathogenetic mechanisms such as leukaemic deposits do not return to their pre-morbid states following disease control despite the use of the currently available treatment protocols.
  • For future research, more still needs to be done to elicit other uncommon pathogenetic mechanisms underlying these complications with a view to finding specific treatment measures for worrisome chronic myeloid leukaemia-related sensori-neural deficits.
  • [MeSH-major] Brain Diseases / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Nervous System Diseases / epidemiology. Nervous System Diseases / etiology. Nigeria / epidemiology. Prevalence. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Niger J Clin Pract. 2009 Mar;12(1):112. Emmanuel, J D [corrected to Joseph, D E]; Dorusinmi, M A [corrected to Durosinmi, M A]
  • (PMID = 19140362.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


68. D'Orazio JA, Pulliam JF, Moscow JA: Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion. Pediatr Hematol Oncol; 2008 Jun;25(5):457-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.
  • Though infantile leukemia has a historically poor prognosis, there may be a subset of patients with cutaneous disease whose disease will resolve without therapy.
  • The authors report a case of infantile leukemia cutis who presented with a single subcutaneous chloroma that spontaneously resolved over the course of several weeks and who remains without evidence of disease nearly two years later.
  • After reviewing the literature of congenital leukemia cutis, the authors conclude that withholding chemotherapy in infants with cutaneous myeloid leukemia in the absence of known negative prognostic factors (MLL or BCR-ABL translocations) or progressive disease is clinically indicated.
  • [MeSH-major] Leukemia, Myeloid. Skin Neoplasms
  • [MeSH-minor] Humans. Infant. Remission, Spontaneous. Sarcoma, Myeloid

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569848.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


69. Olivares R, Alfaro J, Díaz MC, Thompson L: [Disseminated fusariosis by Fusarium oxysporum in an adult patient with acute myeloid leukemia and severe febrile neutropenia]. Rev Chilena Infectol; 2005 Dec;22(4):356-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disseminated fusariosis by Fusarium oxysporum in an adult patient with acute myeloid leukemia and severe febrile neutropenia].
  • [Transliterated title] Fusariosis diseminada por Fusarium oxysporum en un paciente adulto con leucemia mieloide aguda y neutropenia severa febril.
  • [MeSH-major] Fusarium. Immunocompromised Host. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications. Neutropenia / complications

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Chilena Infectol. 2006 Mar;23(1):87
  • (PMID = 16341358.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


70. Lam TV, Agovino P, Niu X, Roché L: Linkage study of cancer risk among lead-exposed workers in New Jersey. Sci Total Environ; 2007 Jan 1;372(2-3):455-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers of the stomach, breast, larynx, intrahepatic bile duct, and chronic myeloid leukemia were non-significantly elevated.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Data Collection / methods. Humans. Industry. Middle Aged. New Jersey / epidemiology. Occupational Diseases / chemically induced. Occupational Diseases / epidemiology. Risk Assessment. SEER Program

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. Lead, elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129599.001).
  • [ISSN] 0048-9697
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-45025-40; United States / PHS HHS / / U55/CCU221914
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 2P299V784P / Lead
  •  go-up   go-down


71. Li WX, Cui CB, Cai B, Wang HY, Yao XS: Flavonoids from Vitex trifolia L. inhibit cell cycle progression at G2/M phase and induce apoptosis in mammalian cancer cells. J Asian Nat Prod Res; 2005 Aug;7(4):615-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast to the cell cycle G2/M phase inhibitory main effect on tsFT210 cells, 5 induced mainly apoptosis on human myeloid leukemia K562 cells with a weak inhibition of the cell cycle at the G2/M phase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16087636.001).
  • [ISSN] 1028-6020
  • [Journal-full-title] Journal of Asian natural products research
  • [ISO-abbreviation] J Asian Nat Prod Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavonoids
  •  go-up   go-down


72. Song AX, Yang DL, Wei JL, Yan ZS, Wang M, Jiang EL, Huang Y, Liu QG, Ma QL, Zhai WH, Zhang RL, Feng SZ, Han MZ: [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb;18(1):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis].
  • This study was purposed to evaluate the outcome of patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in complete remission, and to study the prognostic factors.
  • Major end points of study included overall survival (OS), disease free survival (DFS), relapse rate and transplantation related mortality (TRM).
  • Different prognosis was observed between HSCT recipients of alternative donor and HLA-matched related donor (MRD) (3-year DFS was 34.3% vs 60.0%, p = 0.019), between patients of refractory leukemia and the control (3-year DFS was 35.7% vs 58.2%, p = 0.048), between recipients with and without severe aGVHD (3-year DFS was 35.7% vs 54.4%, p = 0.059).
  • Multivariate analysis revealed three negative prognostic factors: donor availability (alternative vs MRD) (p = 0.049, RR = 2.09, 95%CI 1.01 - 4.36), refractory leukemia (p = 0.038, RR = 2.33, 95%CI 1.05 - 5.20) and severe aGVHD (p = 0.040, RR = 2.33, 95%CI 1.04 - 5.20).
  • Donor availability, refractory leukemia and severe aGVHD are confirmed as risk factors of poor prognosis for allo-HSCT patients with AML in CR.


73. Hambley TW, Hait WN: Is anticancer drug development heading in the right direction? Cancer Res; 2009 Feb 15;69(4):1259-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The success of molecularly targeted agents, such as imatinib, has led to expectations of a new era in anticancer drug development, and to a greatly increased focus on targeting as a strategy.
  • However, the number of successes to date is small, and recent results suggest that the success of imatinib, for instance, in treating chronic myelogenous leukemia and gastrointestinal stromal tumor may be the exception rather than the rule.
  • [MeSH-minor] Benzamides. Drug Delivery Systems / methods. Drug Delivery Systems / trends. Gastrointestinal Stromal Tumors / drug therapy. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208831.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


7
Advertisement
4. Servida F, Soligo D, Delia D, Henderson C, Brancolini C, Lombardi L, Deliliers GL: Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia; 2005 Dec;19(12):2324-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
  • The proteasome inhibitor PSI is potently cytotoxic in vitro against human chronic myeloid leukemia (CML) and acute myeloid leukemias (AML).
  • PSI potentiated the toxicity of a number of chemotherapeutic agents in myeloid leukemia but not in MM cell lines, while in combination with therapeutic proteasome inhibitor PS-341 (Bortezomib) it had a synergistic effect.
  • [MeSH-major] Cysteine Proteinase Inhibitors / pharmacology. Leukemia, Myeloid / drug therapy. Multiple Myeloma / drug therapy. Oligopeptides / pharmacology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224484.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cysteine Proteinase Inhibitors; 0 / Oligopeptides; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal; EC 3.4.22.- / Caspases
  •  go-up   go-down


75. Rytting ME, Kantarjian H, Albitar M: Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. Am J Clin Pathol; 2009 Aug;132(2):182-5; quiz 306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity.
  • Expression of a high level of myeloperoxidase (MPO) as a sole myeloid marker in acute leukemias that express typical lymphoblastic markers is unusual.
  • Herein we report 5 cases of MPO+, otherwise typical acute lymphoblastic leukemia (ALL) without the expression of other myeloid markers.
  • The striking feature of most of these cases is a morphologic picture reminiscent of that seen in Burkitt-like B-cell ALL with basophilic cytoplasm and vacuoles but no expression of surface immunoglobulin.
  • All cases responded to ALL therapy and should be distinguished from myeloid leukemia and from Burkitt leukemia/lymphoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Peroxidase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605811.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


76. Miettinen M, Kraszewska E, Sobin LH, Lasota J: A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer; 2008 Feb 1;112(3):645-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.
  • These tumors most commonly occur in the stomach and small intestine and encompass a clinical spectrum from benign to malignant.
  • BACKGROUND: Nine patients (2 with gastric GISTs and 7 with GISTs of the small intestine) developed myeloid leukemia.
  • There were 6 patients (4 women and 2 men) with acute myeloid leukemia (AML), including 1 case of promyelocytic and 1 case of myelomonocytic leukemia, and 3 patients (2 men and 1 woman) with chronic myeloid leukemia (CML).
  • RESULTS: The leukemias developed 1.7 to 21 years after the GIST (median interval, 6 years).
  • None of the GIST patients had received radiotherapy or chemotherapy prior to the leukemia diagnosis.
  • Eight of 9 patients died of leukemia, and none died of GIST.
  • Standardized incidence ratios (SIRs) and their 95% confidence intervals (95% CIs) were calculated comparing the incidences of AML/CMLs in GIST patients with those in the 2000 through 2003 U.S. population.
  • CONCLUSIONS: Additional epidemiologic, clinical, and pathogenetic studies are needed to understand the apparent nonrandom association between GIST and myeloid leukemia.
  • [MeSH-major] Gastrointestinal Stromal Tumors / epidemiology. Intestinal Neoplasms / epidemiology. Leukemia, Myeloid / epidemiology. Stomach Neoplasms / epidemiology


77. Amitrano L, Guardascione MA, Schiavone EM, Brancaccio V, Antinolfi I, Iannaccone L, Ferrara F, Balzano A: Hepatic vein thrombosis leading to fulminant hepatic failure in a case of acute non-promyelocytic myelogenous leukemia. Blood Coagul Fibrinolysis; 2006 Jan;17(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic vein thrombosis leading to fulminant hepatic failure in a case of acute non-promyelocytic myelogenous leukemia.
  • Budd-Chiari syndrome is a rare disease due to occlusion of the hepatic veins often presenting with acute liver failure.
  • Common causes of Budd-Chiari syndrome are chronic myeloproliferative disorders, while acute leukemia has been associated with hepatic vein thrombosis in only two cases in the literature to date.
  • We report a case of Budd-Chiari syndrome complicating a non-promyelocytic acute myelogenous leukemia leading to fulminant hepatic failure.
  • [MeSH-major] Budd-Chiari Syndrome / etiology. Leukemia, Myeloid, Acute / complications. Liver Failure, Acute / etiology


78. Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA: Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene; 2005 May 5;24(20):3257-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
  • In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in the absence of IL-3.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. Glucose / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735728.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Benzamides; 0 / Cytokines; 0 / Enzyme Inhibitors; 0 / Glucose Transporter Type 1; 0 / Interleukin-3; 0 / Monosaccharide Transport Proteins; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 0 / SLC2A1 protein, human; 8A1O1M485B / Imatinib Mesylate; 9G2MP84A8W / Deoxyglucose; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; IY9XDZ35W2 / Glucose; N12000U13O / Doxycycline
  •  go-up   go-down


79. Kern W, Haferlach T: [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis]. Med Klin (Munich); 2005 Jan 15;100(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
  • In the setting of diagnosing acute myeloid leukemias (AML) this method is used not only to subclassify AML and separate it from acute lymphoblastic and biphenotypic leukemias but also for the identification of leukemia-associated aberrant immunophenotypes (LAIPs).
  • Since these LAIPs are defined individually for each patient, leukemic bone marrow cells can be detected during the course of treatment using the LAIP allowing the quantification of minimal residual disease (MRD) which is not detectable by cytomorphology.
  • Due to its close correlation with the course of the disease and with the risk of relapse the MRD represents an important prognostic parameter which is increasingly used for stratification of therapy in clinical trials.
  • [MeSH-major] Flow Cytometry / methods. Leukemia, Myeloid, Acute / diagnosis. Neoplasm, Residual / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654545.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Epitopes; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


80. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O: In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs; 2008 Nov;17(11):1623-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: All-trans retinoic acid (ATRA) is mandatory in the treatment of acute promyelocytic leukaemia (APL).
  • Experimental studies suggest that ATRA can induce differentiation and apoptosis in leukaemia cells also for other acute myelogenous leukaemia (AML) subtypes, but the clinical observations are conflicting.
  • DESIGN AND METHODS: Twenty-two AML patients with non-APL disease received oral ATRA alone (22.5 mg/m2 twice daily) for two days, the patients thereafter continued ATRA together with valproic acid and theophylline.
  • Serum/plasma samples were collected before and after 2 days of ATRA, peripheral blood AML cells were collected from all 12 patients with circulating leukaemia cells (ClinicalTrials.gov NCT00175812; EudraCT no. 2004-001663-22).
  • Circulating leukaemia cells derived during therapy had increased intracellular levels of P21 (mean increase in mean fluorescence intensity (MFI) being 18.2%, p = 0.017), and decreased levels of Gata-2 (mean decrease in MFI 19%, p = 0.026), NF-kappaB p65 (mean decrease in MFI 15.4%, p = 0.033) and Bcl-2 (mean decrease in MFI 7.2%, p = 0.005).
  • CONCLUSIONS: In vivo ATRA treatment in AML affects leukaemic cell morphology, regulation of cell cycle progression and apoptosis, and possibly also microvascular endothelial cell functions.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922099.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00175812
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Histone Deacetylase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; 5688UTC01R / Tretinoin; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


81. Roskoski R Jr: Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun; 2005 Dec 23;338(3):1307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gain-of-function mutations of Kit are associated with several human neoplasms including acute myelogenous leukemia, gastrointestinal stromal tumors, mastocytomas, and nasal T-cell lymphomas.
  • The juxtamembrane domain inhibits enzyme activity in cis by maintaining the control alphaC-helix and the activation loop in their inactive conformations.
  • STI-571 binds to Kit and Bcr-Abl (the oncoprotein of chronic myelogenous leukemia) at their ATP-binding sites.


82. Bosi A, Bartolozzi B, Guidi S: Allogeneic stem cell transplantation. Transplant Proc; 2005 Jul-Aug;37(6):2667-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main reported indications were as follows: leukemia, lymphoproliferative diseases, myelodysplasia, and nonmalignant diseases such as thalassemia and severe aplastic anemia.
  • In contrast, the availability of the Tyrosine kinase inhibitor (STI-571) for treatment of patients affected by chronic myelogenous leukemia, which was formerly the main indication for HSCT, has produced a dramatic decrease in the number of transplantations in this setting.
  • HSCT performed in the early phases of disease and in young patients offers more than a 50% cure rate.
  • As regards relapses, they correlate with disease status at the time of transplantation.
  • [MeSH-minor] Hematologic Diseases / therapy. Humans. Italy. Leukemia / therapy. Retrospective Studies. Tissue Donors / statistics & numerical data. Transplantation, Autologous / statistics & numerical data. Transplantation, Homologous / statistics & numerical data

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182779.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Gözdaşoğlu S, Ertem M, Uysal Z, Babacan E, Yüksel M, Bökesoy I, Sunguroğlu A, Arcasoy A, Çavdar A: Acute myeloid leukemia in Turkish children with Fanconi anemia. One center experience in the period between 1964-1995. Turk J Haematol; 2009 Sep 5;26(3):118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia in Turkish children with Fanconi anemia. One center experience in the period between 1964-1995.
  • [Transliterated title] Fanconi anemili Türk çocuklarında akut miyeloid lösemi. 1964-1995 döneminde bir merkezin deneyimleri.
  • OBJECTIVE: Fanconi's anemia(FA) is an autosomal recessive disorder characterized by a progressive pancytopenia,variable congenital abnormalities and an increased risk for the development of acute myeloid leukemia (AML).
  • CONCLUSION: Acute myelomonocytic type in three cases and acute monocytic type in one patient were diagnosed in our series.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265494.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


84. van der Meer A, Schaap NP, Schattenberg AV, van Cranenbroek B, Tijssen HJ, Joosten I: KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Mol Immunol; 2008 Aug;45(13):3631-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
  • The effect of NK alloreactivity in HLA identical SCT is still under debate and in particular in transplantation for chronic myeloid leukemia (CML) the data are very limited and with conflicting outcome.
  • The aim of our study was to evaluate the effect of KIR genes and KIR ligands on leukemia free survival (LFS) and relapse rate in a well-defined, homogeneous group of CML patients phase upon HLA identical sibling SCT.
  • In the latter group, the stimulatory KIR2DS5 gene was associated with improved leukemia free survival (p=0.007; hazard ratio 4.3; 95% confidence interval 1.3-6.7) and lower relapse rates (p=0.028; HR 4.3, 95% CI 1.1-9.1).
  • [MeSH-major] Genetic Linkage. HLA Antigens / immunology. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Receptors, KIR / genetics
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Gene Frequency. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous / immunology


85. Park TH, Kwon HC, Kim HJ, Han JY, Jeong JS, Han HY, Seo C, Kwak JY, Park JI: Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells. Exp Mol Med; 2005 Oct 31;37(5):507-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells.
  • Imatinib mesylate is a selective Bcr/Abl kinase inhibitor and an effective anticancer agent for Bcr/Abl-positive chronic myelogenous leukemia.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia, Myeloid / genetics. Mutagenesis, Insertional / genetics. Piperazines / pharmacology. Point Mutation / genetics. Pyrimidines / pharmacology

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264277.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Benzamides; 0 / Nucleotides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


86. Carella AM, Lerma E: Imatinib mesylate in chronic myeloid leukemia. Curr Stem Cell Res Ther; 2007 Sep;2(3):249-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in chronic myeloid leukemia.
  • Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology.
  • Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation.
  • According to five-years experience with this drug, it is recommended that the golden standard for initial treatment of newly diagnosis chronic myeloid leukemia patients should be 400 mg Imatinib daily.
  • In this brief review, we discuss the current tools for the effective management of chronic myeloid leukemia with Imatinib, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how Imatinib-treated patients should be monitored.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Chronic-Phase / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use


87. Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H: The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother; 2010 Jun;33(5):523-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
  • Adoptive immunotherapy is an important therapy option to reduce relapse rates after stem-cell transplantation in patients suffering from acute myeloid leukemia and myelodysplastic syndromes.
  • Myeloid leukemic cells can regularly be induced to differentiate into leukemia-derived dendritic cells (DC(leu)), regaining the stimulatory capacity of professional dendritic cells (DCs) while presenting the known/unknown leukemic antigen repertoire.
  • To further elicit DC/DC(leu)-induced T-cell-response patterns, we generated DC from 17 Acute myeloid leukemia (AML) and 2 myelodysplastic syndrome cases and carried out flowcytometry and (functional) nonradioactive fluorolysis assays before/after mixed lymphocyte cultures of matched (allogeneic) donor T cells (n=6), T cells prepared at relapse after stem-cell transplantation (n=4) or (autologous) patients' T cells (n=7) with blast containing mononuclear cells ("MNC") or DC(leu) ("DC").
  • We could define DC subtypes and cut-off proportions of DC subtypes/qualities (mature DC/DC(leu)) after "DC" priming, which were predictive for an antileukemic activity of primed T cells and the clinical course of the disease after immunotherapy (allogeneic stem-cell transplantation/donor lymphocytes infusion/therapy).
  • In summary, our data show that the composition and quality of DC after a mixed lymphocyte culture-priming phase is predictive for a successful ex vivo antileukemic response, especially with respect to proportions of mature and leukemia-derived DC.
  • These data contribute not only to predict DC-mediated functions or the clinical course of the diseases but also to develop and refine DC-vaccination strategies that may pave the way to develop and modify adoptive immunotherapy, especially for patients at relapse after allogeneic stem-cell transplantation.
  • [MeSH-major] Dendritic Cells / metabolism. Immunotherapy, Adoptive. Leukemia, Myeloid, Acute / diagnosis. Myelodysplastic Syndromes / diagnosis. T-Lymphocytes / metabolism


88. Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J: Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol; 2008 Feb 1;26(4):577-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
  • This reduction makes it possible for patients who are ineligible for high-dose myeloablative conditioning allo-SCT to benefit from graft-versus-leukemia reaction.
  • In this multicenter, prospective study of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), we investigated the efficacy of RIC allo-SCT from a human leukocyte antigen-identical sibling by using a regimen that uses fludarabine and busulfan.
  • Graft-versus-host disease (GVHD) prophylaxis consisted of cyslosporine and methotrexate or mycophenolate mofetil.
  • The 1- and 4-year relapse cumulative incidences were 23% and 37%, respectively, and leukemia recurrence was the main cause of death.
  • The 4-year disease-free survival (DFS) and overall survival (OS) rates were 43% and 45%, respectively.
  • CONCLUSION: Our results confirm the capacity of this RIC regimen to obtain long-term remissions in patients ineligible for a conventional allo-SCT.
  • [MeSH-major] Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Chronic Disease. Disease-Free Survival. Drug Therapy, Combination. Female. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Multivariate Analysis. Myeloablative Agonists / administration & dosage. Prospective Studies. Remission Induction. Survival Analysis. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


89. Gogtay J, Chahchad S, Jadhav S, Purandare S: Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. Int J Hematol; 2010 Dec;92(5):772-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelomonocytic, Chronic / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Hematol. 2010 Jan;91(1):104-6 [20054670.001]
  • [Cites] Int J Hematol. 2010 Jan;91(1):104-6 [20054670.001]
  • (PMID = 21082296.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Drugs, Generic; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


90. Hayashi T, Ishioka M, Ito N, Kato Y, Nakagawa H, Hatano H, Mizuki N: Bilateral herpes simplex keratitis in a patient with chronic graft-versus-host disease. Clin Ophthalmol; 2008 Jun;2(2):457-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral herpes simplex keratitis in a patient with chronic graft-versus-host disease.
  • PURPOSE: To describe a case of bilateral herpes simplex keratitis accompanying chronic graft-versus-host disease (GVHD).
  • CASE REPORT: An 11-year-old boy with myelocytic leukemia underwent allogeneic bone marrow transplantation.
  • CONCLUSIONS: Herpes keratitis should be considered in the differential diagnosis of bilateral keratitis in patients with reduced immunocompetence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 1991 Oct 15;112(4):468-9 [1928259.001]
  • [Cites] Trans Ophthalmol Soc U K. 1975 Jul;95(2):267-76 [775699.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(10):1031-5 [15048138.001]
  • (PMID = 19668737.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2693989
  • [Keywords] NOTNLM ; bilateral herpes simplex keratitis / bone marrow transplant / chronic graft-versus-host disease / corneal herpes / dry eyes
  •  go-up   go-down


91. Brière J: [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome]. Bull Acad Natl Med; 2007 Mar;191(3):535-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
  • [Transliterated title] Thrombocytémie essentielle. Apport de la mutation V617F de JAK2 pour la stratégie diagnostique, la physiopathologie et les modalités évolutives.
  • Secondary thrombocytosis is a reactive process in relation with acute or chronic inflammatory diseases, or asplenia.
  • However, the most frequent causes of chronic thrombocytosis in adults are the so-called chronic myeloproliferative syndromes (chronic myelocytic leukaemia, polycythemia vera, primary myelofibrosis, essential thrombocytemia), and to a lesser extent, myelodysplastic syndromes.
  • In the course of these disorders, thrombocytosis is often the first recognized abnormality.
  • Chronic myelocytic leukaemia is easily diagnosed owing to the presence of either the Philadelphia chromosome or the BCR-ABL fusion gene product.
  • The next step still relies upon a distinction according to the PVSG or the WHO criteria of Polycythemia Vera (PV) and Idiopathic myelo fibrosis (IMF) to finally confirm genuine Essential Thrombocythemia (ET).
  • The exclusion of PV and of IMF, including pre fibrotic and early fibrotic forms is still required for the diagnosis of "true" ET.
  • Disease stratification and treatment strategy are targeted on the evaluation and prevention of vascular complications.
  • Acute leukaemia or myelodysplasia, and other clonal progressions like myelofibrotic transformation, are infrequent and delayed events.
  • [MeSH-minor] Adult. Biopsy. Bone Marrow / pathology. Cohort Studies. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Mutation. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Philadelphia Chromosome. Polycythemia Vera / diagnosis. Polycythemia Vera / genetics. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / genetics. Prognosis. Risk Factors. World Health Organization

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072652.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 56
  •  go-up   go-down


92. Liu YC, Miyazawa K, Sashida G, Kodama A, Ohyashiki K: Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer Genet Cytogenet; 2006 Aug;169(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly.
  • The deletion of the long arm of chromosome 20, or del(20q), is a common cytogenetic abnormality in various myeloid disorders but is less commonly seen in lymphoid neoplasms.
  • Reviewing all 11 reported cases of plasma cell dyscrasia possessing sole del(20q), including our case, none of 4 cases with del(20q) as an initial anomaly developed myelodysplastic syndrome-acute myeloid leukemia (MDS/AML), but at least 3 cases with del(20q) appearing after chemotherapy developed MDS/AML at or after the time of del(20q).
  • We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.


93. Haylock DN, Nilsson SK: Osteopontin: a bridge between bone and blood. Br J Haematol; 2006 Sep;134(5):467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of Opn is a feature of haemopoietic malignancies, such as multiple myeloma and chronic myeloid leukaemia, although its exact role in the aetiology and progression of these diseases remains unclear.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848793.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  • [Number-of-references] 96
  •  go-up   go-down


94. Suzuki T, Koyama Y, Ichikawa H, Tsushima K, Abe K, Hayakawa S, Kuruto-Niwa R, Nozawa R, Isemura M: 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct; 2005;30(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells.
  • The physiologically active metabolite of vitamin D(3), 1alpha,25-dihydroxyvitamin D(3) (DVD), is a potent inducer of cell differentiation in human myeloid leukemia cells.
  • [MeSH-major] Calcitriol / pharmacology. Eukaryotic Initiation Factor-2 / genetics. Gene Expression Regulation, Leukemic / drug effects

  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951637.001).
  • [ISSN] 1347-3700
  • [Journal-full-title] Cell structure and function
  • [ISO-abbreviation] Cell Struct. Funct.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-2; 0 / Neoplasm Proteins; FXC9231JVH / Calcitriol
  •  go-up   go-down


95. Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini S, Kwong YL, Liang R, Lau GK: Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation. J Clin Virol; 2005 Feb;32(2):173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Two male patients with acute myeloid leukemia and light chain myeloma, respectively, developed HBV-related hepatitis more than 2 years after HCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Hepatitis B / immunology. Hepatitis B / transmission. Hepatitis B Antibodies / blood. Sexually Transmitted Diseases, Viral / transmission. Transplantation, Homologous / adverse effects
  • [MeSH-minor] Adult. DNA, Viral / analysis. Female. Hepatitis B Surface Antigens / immunology. Hepatitis B virus / classification. Hepatitis B virus / genetics. Hepatitis B virus / immunology. Heterosexuality. Humans. Immunity. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653422.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


96. Lichtman MA: Battling the hematological malignancies: the 200 years' war. Oncologist; 2008 Feb;13(2):126-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The delineation of the hematological malignancies began near the end of the first third of the 19th century with the recognition of the similarity among cases with lymph node tumors and an enlarged spleen (Hodgkin's disease).
  • Descriptions of chronic and acute leukemia and myeloma followed thereafter.
  • In the first years of the 20th century the discovery of x-radiation permitted palliative orthovoltage radiation therapy of Hodgkin's disease.
  • Despite remarkable progress, including the ability to cure acute leukemia in about 70% of children, cure several genetic variants of acute myelogenous leukemia in younger adults, cure some cases of lymphoma in children and younger adults, and induce prolonged remission in many affected persons, the majority of patients face an uncertain outcome and shortened life.
  • These challenges will be gradually overcome, if we (a) develop new models of cooperation among academia, industry, and government, (b) continue the growth of international participation in cancer research (more keen minds to the task), and (c) convince the governments of the world, including that of the U.S., that an investment in minimizing the effects of cancer is as important as defending against other threats to the welfare and longevity of their citizens.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia / drug therapy. Lymphoma / drug therapy. Multiple Myeloma / drug therapy
  • [MeSH-minor] Age Factors. Genetic Predisposition to Disease. History, 19th Century. History, 20th Century. History, 21st Century. Humans. Risk Factors. Time Factors. Treatment Outcome


97. Kuendgen A, Gattermann N: Valproic acid for the treatment of myeloid malignancies. Cancer; 2007 Sep 1;110(5):943-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproic acid for the treatment of myeloid malignancies.
  • Recently, it was demonstrated that VPA also acts as a histone deacetylase inhibitor and induces differentiation and apoptosis in a variety of malignant cells in vitro.
  • Clinical trials with VPA have focused on acute myeloid leukemia and the myelodysplastic syndromes.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, Myeloid / drug therapy. Tretinoin / pharmacology. Valproic Acid / pharmacology
  • [MeSH-minor] Acute Disease. Cell Line, Tumor. Drug Synergism. Drug Therapy, Combination. Histone Deacetylase Inhibitors. Humans

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 May 15;112(10):2324-5; author reply 2325 [18348302.001]
  • (PMID = 17647267.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid
  • [Number-of-references] 75
  •  go-up   go-down


98. Chang G, Meadows ME, Jones JA, Antin JH, Orav EJ: Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). Am J Drug Alcohol Abuse; 2010 Jan;36(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).
  • METHOD: Prospective cohort study of 106 adults with chronic myelogenous leukemia or primary myelodysplastic syndrome.
  • CONCLUSION: The results of this study highlight the potential significance of substance use disorders, and lifetime cocaine diagnoses in particular, on treatment outcome for people with chronic myelogenous leukemia or myelodysplastic syndrome.


99. Löwenberg B: Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program; 2008;:1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia: the challenge of capturing disease variety.
  • The difference between success and failure of treatment of acute myeloid leukemia (AML) is largely determined by genotypic leukemia-specific differences among patients.
  • The diversity of AML genotypes result from somatic genetic alterations settling down in succession in an individual's leukemia clone during the development of the disease.
  • Gene mutations, gene expression abnormalities and other molecular alterations (e.g., microRNA variations) affect critical functions in AML cells, and may exert profound effects on the therapeutic response and outcome of the disease.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074046.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / MECOM protein, human; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors
  • [Number-of-references] 80
  •  go-up   go-down


100. Vermeersch P, Zachee P, Brusselmans C: Acute myeloid leukemia with bone marrow necrosis and Charcot Leyden crystals. Am J Hematol; 2007 Nov;82(11):1029
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with bone marrow necrosis and Charcot Leyden crystals.
  • [MeSH-major] Glycoproteins / metabolism. Leukemia, Myeloid, Acute / complications. Lysophospholipase / metabolism. Osteonecrosis / etiology






Advertisement